Clinical Trials

Prostatic Neoplasms

NCT03344211 2026-02-27

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

30 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

37 enrolled 10 charts

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

100 enrolled

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

NCT04455750 2026-02-05

CASPAR

61 enrolled

Prostatic Neoplasms

NCT03246347 2026-01-23

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

40 enrolled 12 charts

Prostatic Neoplasms

NCT06734130 2026-01-21

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

188 enrolled 25 charts

Prostatic Neoplasms

NCT02452008 2025-12-19

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

60 enrolled

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

32 enrolled

Prostatic Neoplasms

NCT02312557 2025-12-03

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

58 enrolled 13 charts

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT02023463 2025-11-25

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT04335682 2025-11-04

ARACOG

111 enrolled

Prostatic Neoplasms

NCT04557449 2025-10-01

CDK4i

BreastGastrointestinalGenitourinarySarcomaThoracic

362 enrolled

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT02194842 2025-09-19

PEACE III

446 enrolled

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT05011188 2025-08-27

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

44 enrolled

Prostatic Neoplasms

NCT01990196 2025-08-17

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

45 enrolled

Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

439 enrolled

Prostatic Neoplasms

NCT04471974 2025-07-22

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

61 enrolled

Prostatic Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

1,244 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT02446444 2025-05-30

ENZARAD

802 enrolled

Prostatic Neoplasms

NCT04262154 2025-04-27

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

28 enrolled

Prostatic Neoplasms

NCT02446405 2025-02-06

ENZAMET

1,125 enrolled

Prostatic Neoplasms

NCT03700099 2024-04-15

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

30 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT00268476 2023-04-18

STAMPEDE

11,992 enrolled